CNS Pharmaceuticals, Inc.
CNSP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $9,864 | $12,130 | $13,048 | $6,461 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $883 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1,528 | $2,008 | $674 | $1,315 |
| Total Curr. Assets | $11,392 | $14,138 | $13,722 | $8,659 |
| Property Plant & Equip (Net) | $3 | $4 | $5 | $6 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $474 | $366 | $22 | $36 |
| Total NC Assets | $478 | $370 | $27 | $42 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $11,869 | $14,508 | $13,749 | $8,701 |
| Liabilities | – | – | – | – |
| Payables | $1,928 | $1,261 | $2,569 | $2,198 |
| Short-Term Debt | $31 | $122 | $211 | $326 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $0 | $0 | $0 | $0 |
| Total Curr. Liab. | $1,959 | $1,383 | $2,779 | $2,524 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,959 | $1,383 | $2,779 | $2,524 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1 | $1 | $3 | $1 |
| Retained Earnings | -$94,319 | -$91,101 | -$88,726 | -$84,425 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $9,910 | $13,125 | $10,970 | $6,177 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $11,869 | $14,508 | $13,749 | $8,701 |
| Net Debt | -$9,833 | -$12,008 | -$12,837 | -$6,135 |